{"denomUnitsSelected":"Participants","description":"Evaluated using Kaplan-Meier methodology.","reportingStatus":"NOT_POSTED","timeFrame":"Time from first response to progression, assessed up to 3 years","title":"Duration of Response in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression","type":"OTHER_PRE_SPECIFIED"}